

Biocon Limited

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

September 20, 2019

www.biocon.com

| | |
|---|--|
| To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 | To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- Biocon |
|---|--|

Dear Sir/Madam,

Sub: "U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru".

Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

"The U.S. FDA conducted a Pre-Approval Inspection (PAI) at two of our new Biologics Manufacturing facilities in Bengaluru from Sep 10 to Sep 19, 2019. The inspection included a new Drug Substance (DS) and a Drug Product (DP) unit.

*At the conclusion of the inspection we received a Form 483 with four observations for the new DS facility, three observations for the new DP facility and one general observation. We are confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously. The Pre-Approval Inspection of our new facilities does not have any impact on our current commercialization plans from our existing facilities." - **Company Spokesperson***

We request you to kindly take this on record as per the requirement of LODR and oblige.

Thanking You,

Yours faithfully,
For **Biocon Limited**



Mayank Verma
Company Secretary & Compliance Officer